Labsystems Diagnostics, based in Finland, has been a forerunner in innovative diagnostic research and development for nearly 40 years, pioneering new technologies for newborn screening and point of care testing. Among the market leaders in newborn screening, our neonatal products save and improve the lives of babies in more than 70 countries.
Being a one-stop solution provider for newborn screening, offering the most comprehensive and high-quality screening kits, supported by best-in-class automation capabilities and user-friendly software, we have a strong record of technology leadership, including pioneering research to enable the early detection of diseases.
Labsystems Diagnostics develops, manufactures, and markets high-quality and safe diagnostic products, which are based on defined quality specifications and fulfill relevant regulatory requirements. The strengths of Labsystems Diagnostics are know-how and continuous product development, which we use to respond to clinical needs.
Our quality target is to deliver products fulfilling our quality criteria in agreed time and ensure at all times the patient safety and the customer satisfaction. To achieve our goals in quality, the whole personnel is conscious about the importance of high quality.
Labsystems Diagnostics was the first to:
- Develop fluorometric PKU [Phenylketonuria] tests for NBS
- Provide PKU assays in micro-plate format
Neonatal screening or Newborn Screening involves the screening of newborns in the first days of their lives for inborn errors of metabolism and certain disorders that can hinder the normal development of the baby. These disorders are not apparent at the time of the baby's birth, but have the potential to cause permanent neurological, cognitive, tactile, and physical damage in the child. Early detection of such diseases enables initiating suitable interventions to prevent concerning outcomes.
Our products categories:
Labsystems Diagnostics, based in Finland, has been a forerunner in innovative diagnostic research and development for nearly 40 years, pioneering new technologies for newborn screening and point of care testing. Among the market leaders in newborn screening, our neonatal products save and improve the lives of babies in more than 70 countries.
Being a one-stop solution provider for newborn screening, offering the most comprehensive and high-quality screening kits, supported by best-in-class automation capabilities and user-friendly software, we have a strong record of technology leadership, including pioneering research to enable the early detection of diseases.
Labsystems Diagnostics develops, manufactures, and markets high-quality and safe diagnostic products, which are based on defined quality specifications and fulfill relevant regulatory requirements. The strengths of Labsystems Diagnostics are know-how and continuous product development, which we use to respond to clinical needs.
Our quality target is to deliver products fulfilling our quality criteria in agreed time and ensure at all times the patient safety and the customer satisfaction. To achieve our goals in quality, the whole personnel is conscious about the importance of high quality.
Labsystems Diagnostics was the first to:
- Develop fluorometric PKU [Phenylketonuria] tests for NBS
- Provide PKU assays in micro-plate format
Neonatal screening or Newborn Screening involves the screening of newborns in the first days of their lives for inborn errors of metabolism and certain disorders that can hinder the normal development of the baby. These disorders are not apparent at the time of the baby's birth, but have the potential to cause permanent neurological, cognitive, tactile, and physical damage in the child. Early detection of such diseases enables initiating suitable interventions to prevent concerning outcomes.
Our products categories:
